HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 16
Maximum Age: 45
Healthy Volunteers: f
View:
• Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening
Locations
United States
California
Clinical Trial Site
RECRUITING
Los Angeles
Clinical Trial Site
RECRUITING
Orange
Florida
Clinical Trial Site
RECRUITING
Miami
Kentucky
Clinical Trial Site
RECRUITING
Lexington
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2026-07-30
Estimated Completion Date: 2028-11-29
Participants
Target number of participants: 24
Treatments
Experimental: ALN-6400 (Treatment Group A)
Participants will be administered multiple doses of ALN-6400.
Experimental: ALN-6400 (Treatment Group B)
Participants will be administered multiple doses of ALN-6400.
Related Therapeutic Areas
Sponsors
Leads: Alnylam Pharmaceuticals